Innovation in biologics drug product development & manufacture
- At: 2017 FIP Congress in Stockholm (Sweden)
- Type: Presentation
- By: MAHLER, Hanns-Christian (Lonza AG, Drug Product Services, Basel, Switzerland)
- Co-author(s): Hanns-Christian Mahler: Drug Product Services, Lonza AG, Basel, Switzerland
To date, Biologics account for one third of annual approvals. Biologics generally have to be administered by parenteral administration (injection, infusion or implant) in order to achieve adequate systemic exposure and thus, ensure efficacy and safety, whilst ensuring efficient costs. Biologics include molecules derived from recombinant.. The access to the whole abstract and the presentation file is available to FIP members and to congress participants of that specific congress.